ELCC 2016: CheckMate 171, phase 2 trial of nivolumab for advanced squamous cell non-small cell lung cancer

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Enriqueta Felip, MD, PhD, from Vall dHebron Institute of Oncology, Barcelona, Spain, discusses CheckMate 171, a multicenter phase 2 trial of nivolumab, an anti-PD-1 monoclonal antibody, in patients with stage IIIB/IV squamous cell non-small cell lung cancer who have received at least one prior systemic treatment.